drugset / Trial / NCT00332241

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).

NCT00332241

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will compare the effectiveness (how well the drug works) of aripiprazole, flexibly dosed with a placebo, in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).

Timeline

Start
2006-06-01
Primary completion
2008-04-01
Completion
2008-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 5 mg Oral
Subject Aripiprazole Other / unclassified 10 mg Oral
Subject Aripiprazole Other / unclassified 15 mg Oral

Indications